The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidepressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
23
off-label use of terazosin to treat antidepressant-induced sweating
Thomas Jefferson University, Department of Psychiatry
Philadelphia, Pennsylvania, United States
To study whether terazosin 1 to 4 mg/ day is effective in reducing antidepressant-induced sweating
Time frame: 8 weeks
To test a novel device for ambulatory monitoring of sweating which is required to study this phenomenon since ADIES is usually episodic
Time frame: 8 weeks
To determine if the severity of sweating at baseline is correlated with baseline urinary norepinephrine levels
Time frame: 8 weeks
To determine if response to treatment correlated with baseline urinary norepinephrine levels and with changes in these levels during the study.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.